Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)
Conclusion: The purpose of this guideline is to provide all healthcare providers with high-quality recommendations for the clinical use of fondaparinux and to improve the rational use of the drug in clinical practice. Currently, there is a lack of a dedicated antidote for the management of fondaparinux. The clinical investigation of activated prothrombin complex concentrate (APCC) or recombinant activated factor VII (rFⅦa) as potential reversal agents is still pending. This critical gap necessitates heightened scrutiny and research emphasis, potentially constituting a novel avenue for future inquiries into fondaparinux s...
Source: Frontiers in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Source Type: research
